1,332 results on '"Tracy, J"'
Search Results
2. Knowledge Sharing in Auditor-Provided Tax Services: Experiences of Audit and Tax Personnel
- Author
-
Candice T. Hux, Jean C. Bedard, and Tracy J. Noga
- Subjects
Accounting ,Finance - Abstract
Research generally finds positive audit and tax outcomes associated with auditor-provided tax services (APTS), attributing knowledge sharing (KS) between tax and audit as the underlying cause but not observing it. This study contributes to the APTS literature by investigating experienced audit and tax professionals’ perspectives about when and how KS occurs. Results imply that KS occurs in two phases and is enhanced or inhibited by multiple factors related to knowledge relevance, motivation, opportunities, and culture. First, audit and tax personnel often share client information and their domain expertise while interacting during the audit, which enables identifying potentially valuable APTS. Second, further KS can occur during/following APTS performance, and APTS results may be shared back to benefit the audit. Our evidence shows that key factors may vary across phases, underscoring the importance of considering the full APTS process. Based on our findings, we suggest a number of future research opportunities. JEL Classifications: M41; M42.
- Published
- 2023
3. Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case–control study
- Author
-
Vanessa L Kronzer, Keigo Hayashi, Kazuki Yoshida, John M Davis, Gregory C McDermott, Weixing Huang, Paul F Dellaripa, Jing Cui, Vivi Feathers, Ritu R Gill, Hiroto Hatabu, Mizuki Nishino, Rachel Blaustein, Cynthia S Crowson, William H Robinson, Jeremy Sokolove, Katherine P Liao, Michael E Weinblatt, Nancy A Shadick, Tracy J Doyle, and Jeffrey A Sparks
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy - Published
- 2023
4. Transforming Collection Development through Three Rounds of Emergency Funding
- Author
-
Tracy J. Gilmore, Khue Duong, and Tiffini Travis
- Subjects
Strategy and Management ,Library and Information Sciences - Published
- 2023
5. <scp>TREM2</scp> ‐dependent microglial function is essential for remyelination and subsequent neuroprotection
- Author
-
Yuanyuan Wang, Roxanne V. Kyauk, Yun‐An A. Shen, Luke Xie, Mike Reichelt, Han Lin, Zhiyu Jiang, Hai Ngu, Kimberle Shen, Jacob J. Greene, Morgan Sheng, and Tracy J. Yuen
- Subjects
Cellular and Molecular Neuroscience ,Neurology - Published
- 2023
6. Quantitative Interstitial Abnormality Progression and Outcomes in the Genetic Epidemiology of COPD and Pittsburgh Lung Screening Study Cohorts
- Author
-
Bina Choi, Najma Adan, Tracy J. Doyle, Ruben San José Estépar, Rola Harmouche, Stephen M. Humphries, Matthew Moll, Michael H. Cho, Rachel K. Putman, Gary M. Hunninghake, Ravi Kalhan, Gabrielle Y. Liu, Alejandro A. Diaz, Stefanie E. Mason, Farbod N. Rahaghi, Carrie L. Pistenmaa, Nicholas Enzer, Clare Poynton, Gonzalo Vegas Sánchez-Ferrero, James C. Ross, David A. Lynch, Fernando J. Martinez, MeiLan K. Han, Russell P. Bowler, David O. Wilson, Ivan O. Rosas, George R. Washko, Raúl San José Estépar, and Samuel Y. Ash
- Subjects
Pulmonary and Respiratory Medicine ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine - Published
- 2023
7. Approaches for optimizing venous thromboembolism prevention in injured patients: Findings from the consensus conference to implement optimal venous thromboembolism prophylaxis in trauma
- Author
-
Amanda L. Teichman, Bryan A. Cotton, James Byrne, Navpreet K. Dhillon, Allison E. Berndtson, Michelle A. Price, Tracy J. Johns, Eric J. Ley, Todd Costantini, and Elliott R. Haut
- Subjects
Surgery ,Critical Care and Intensive Care Medicine - Published
- 2022
8. Addressing population health inequities: investing in the social determinants of health for children and families to advance child health equity
- Author
-
Rachel L.J. Thornton and Tracy J. Yang
- Subjects
Pediatrics, Perinatology and Child Health - Published
- 2022
9. Practices and Procedures in Clinical Pediatric Exercise Laboratories in North America
- Author
-
Kelli M. Teson, Jessica S. Watson, Sandra K. Knecht, Wayne A. Mays, Tracy J. Curran, David D. Williams, Paul Rebovich, Stephen M. Paridon, and David A. White
- Subjects
Surveys and Questionnaires ,North America ,Pediatrics, Perinatology and Child Health ,Exercise Test ,Humans ,Physical Therapy, Sports Therapy and Rehabilitation ,Orthopedics and Sports Medicine ,Child ,Laboratories ,Exercise ,United States - Abstract
Interinstitutional differences in clinical pediatric exercise laboratory (CPEL) practices may affect patient care and efficacy of multicenter research. Purpose: To describe current practices/procedures in CPELs and explore differences in CPELs employing exercise physiologists to those that do not. Methods: A 40-item survey was distributed to CPELs in North America focusing on (1) staffing; (2) exercise stress testing (EST) volumes, reporting, and interpretation; and (3) EST procedures/protocols. Results: Of the 55 responses, 89% were in the United States, 85% were children’s hospitals with university affiliation, and 58% were cardiology specific. Exercise physiologists were employed in 56% of CPELs, and 78% had master’s degrees or higher. Certifications were required in most CPELs (92% emergency life-support, 27% professional, and 21% clinical). Median volume was 201 to 400 ESTs per year, 80% used treadmill, and 10% used cycle ergometer as primary modalities. Ninety-three percent of CPELs offered metabolic ESTs, 87% offered pulmonary function testing, 20% used institution-specific EST protocols, and 72% offered additional services such as cardiac/pulmonary rehabilitation. CPELS staffing exercise physiologists performed higher volumes of ESTs (P = .004), were more likely to perform metabolic ESTs (P = .028), participated in more research (P P = .001). Conclusions: Heterogeneity in CPELs staffing and operation indicates need for standardization.
- Published
- 2022
10. Chemorepellent-Loaded Nanocarriers Promote Localized Interference of Escherichia coli Transport to Inhibit Biofilm Formation
- Author
-
Tracy J. Kuper, Leon Z. Wang, Robert K. Prud’homme, Sujit S. Datta, and Roseanne M. Ford
- Subjects
Biomaterials ,Biochemistry (medical) ,Biomedical Engineering ,General Chemistry - Published
- 2022
11. A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
- Author
-
Pierre‐Antoine Juge, Benjamin Granger, Marie‐Pierre Debray, Esther Ebstein, Fabienne Louis‐Sidney, Joanna Kedra, Tracy J. Doyle, Raphaël Borie, Arnaud Constantin, Bernard Combe, René‐Marc Flipo, Xavier Mariette, Olivier Vittecoq, Alain Saraux, Guillermo Carvajal‐Alegria, Jean Sibilia, Francis Berenbaum, Caroline Kannengiesser, Catherine Boileau, Jeffrey A. Sparks, Bruno Crestani, Bruno Fautrel, and Philippe Dieudé
- Subjects
Male ,Arthritis, Rheumatoid ,Rheumatology ,Risk Factors ,Immunology ,Humans ,Immunology and Allergy ,Female ,Prospective Studies ,Lung Diseases, Interstitial ,Lung ,Mucin-5B - Abstract
Patients at high risk of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) would benefit from being identified before the onset of respiratory symptoms; this can be done by screening patients with the use of chest high-resolution computed tomography (HRCT). Our objective was to develop and validate a risk score for patients who have subclinical RA-ILD.Our study included a discovery population and a replication population from 2 prospective RA cohorts (ESPOIR and TRANSLATE2, respectively) without pulmonary symptoms who had received chest HRCT scans. All patients were genotyped for MUC5B rs35705950. After multiple logistic regression, a risk score based on independent risk factors for subclinical RA-ILD was developed in the discovery population and tested for validation in the replication population.The discovery population included 163 patients with RA, and the replication population included 89 patients with RA. The prevalence of subclinical RA-ILD was 19.0% and 16.9%, respectively. In the discovery population, independent risk factors for subclinical RA-ILD were presence of the MUC5B rs35705950 T allele (odds ratio [OR] 3.74 [95% confidence interval (95% CI) 1.37, 10.39]), male sex (OR 3.93 [95% CI 1.40, 11.39]), older age at RA onset (for each year, OR 1.10 [95% CI 1.04, 1.16]), and increased mean Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (for each unit, OR 2.03 [95% CI 1.24, 3.42]). We developed and validated a derived risk score with receiver operating characteristic areas under the curve of 0.82 (95% CI 0.70-0.94) for the discovery population and 0.78 (95% CI 0.65-0.92) for the replication population. Excluding MUC5B rs35705950 from the model provided a lower goodness of fit (likelihood ratio test, P = 0.01).We developed and validated a risk score that could help identify patients at high risk of subclinical RA-ILD. Our findings support an important contribution of MUC5B rs35705950 to subclinical RA-ILD risk.
- Published
- 2022
12. Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years
- Author
-
Jacqueline A. French, Elena Cleary, Dennis Dlugos, Gail Farfel, Kathleen Farrell, Barry Gidal, Caitlin L. Grzeskowiak, Rachel Gurrell, Cynthia Harden, Tracy J. Stalvey, Julia Tsai, Elaine C. Wirrell, David Blum, and Nathan Fountain
- Subjects
Epilepsy ,Adolescent ,Lacosamide ,Neurology ,Seizures ,Humans ,Infant ,Anticonvulsants ,Epilepsies, Partial ,Neurology (clinical) ,Child - Abstract
Drug treatment for children with epilepsy should, ideally, be governed by evidence from adequate and well-controlled clinical studies. However, these studies are difficult to conduct, and so direct evidence supporting the informed use of specific drugs is often lacking. The Research Roundtable for Epilepsy (RRE) met in 2020 to align on an approach to therapy development for focal seizures in children age 1 month2 years of age.The RRE reviewed the regulatory landscape, epidemiology, seizure semiology, antiseizure medicine pharmacology, and safety issues applicable to this population.After reviewing evidence, the conclusion was that pediatric efficacy trials would be impracticable to conduct but a waiver of the regulatory requirement to conduct any study would lead to an absence of information to guide dosing in a critical population. Review of available data and discussion of RRE attendees led to the conclusion that the requirements for extrapolation of efficacy from older children down to infants from age 1 month to2 years old appeared to be met. After the RRE, the US Food and Drug Administration (FDA) approved brivaracetam for use in children with focal epilepsy above the age of 1 month in August 2021 and lacosamide in October 2021, both based on the principle of extrapolation from data in older children.These recommendations should result in more rapid accessibility of antiseizure medications for infants.
- Published
- 2022
13. Incorporating Video Feedback Within a Parent-Implemented Naturalistic Developmental Behavioral Intervention Package Via Telepractice
- Author
-
Ciara L. Ousley, Tracy J. Raulston, and Christina S. Gilhuber
- Subjects
Public Health, Environmental and Occupational Health ,Education - Abstract
Delays in communication are commonly experienced by young children who are not meeting developmental milestones. Early naturalistic developmental behavioral interventions are efficacious, and parents can successfully embed these communication strategies into playtime routines, including when coaching is delivered via telepractice. Video feedback is a strength-based coaching method that has been successfully applied to increase positive parenting behaviors (e.g., descriptive praise, responsivity). However, limited research exists on the use of video feedback as a coaching tool for parents of children with developmental delays for communication interventions. We evaluated the effects of a telepractice-based parent training followed by joint reflections and video feedback coaching on parent strategy use and child communication targets, using a concurrent multiple-baseline across three parent–child dyads design. Parent perceptions of the feasibility and appropriateness of the intervention were positive. We discuss implications and provide suggestions for future research and practice.
- Published
- 2022
14. Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors
- Author
-
Tracy J, Sims, Kristina S, Boye, Susan, Robinson, and Tessa, Kennedy-Martin
- Subjects
Health Policy ,Medicine (miscellaneous) ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,Social Sciences (miscellaneous) - Abstract
Understanding the treatment-related attributes influencing medication-taking behaviors in people with type 2 diabetes (T2D) is important for delivery of patient-centered care. This review aimed to identify and summarize studies in which people with T2D (PwD) directly indicated the treatment-related attributes associated with medication-taking behaviors or intentions.EMBASE and PubMed were searched for studies (Jan 2005-May 2021) reporting the link between PwD-expressed diabetes treatment-related attributes and the decision to initiate, adhere to, or discontinue a T2D medication. Eligible studies reported attributes associated with oral antidiabetes drugs or injectables (not insulin). Studies not explicitly exploring the link between attributes and indicators of behaviors (eg most discrete-choice experiments [DCE] and those interrogating electronic medical records or claims databases) were excluded, as were studies where the link between attribute and behavior came from anyone but the PwD.Of the 6464 studies identified, 16 were included. Studies were conducted across multiple countries; the USA was most represented (n = 8 studies). The impact of treatment attributes was described on indicators of initiation (n = 3), adherence (n = 12), and discontinuation (n = 4). Some studies evaluated multiple behaviors. PwD perspectives were solicited by structured questionnaires (n = 10), qualitative approaches (n = 4), or DCE explicitly exploring the link to medication-taking behaviors (n = 2). Closed- (n = 9) and open-ended questions (n = 7) were employed. Across studies, several factors including glycemic efficacy (n = 9), weight change (n = 9), dosing frequency (n = 9), hypoglycemia (n = 8), gastrointestinal adverse events (n = 8), regimen complexity (n = 6), route of administration (n = 3), and cardiovascular risk (n = 1) were reported as influencing behaviors, being motivators or barriers to initiation, adherence, or discontinuation.Several attributes influence how PwD take their medications. Insights gained directly from PwD have the potential to assist stakeholders in making more informed, patient-centered, treatment decisions, thus choosing and managing medications that PwD are comfortable initiating and persisting with over the longer term.
- Published
- 2022
15. Photographs and Parent Training to Support Conversations about Past Events between Caregivers and Children with Autism
- Author
-
Naima Bhana, Tracy J. Raulston, Ciara Ousley, and Atikah Bagawan
- Subjects
Psychology (miscellaneous) ,Social Sciences (miscellaneous) - Published
- 2023
16. Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy
- Author
-
Tracy J. Lu, Linus Amarikwa, Connie M. Sears, and Andrea L. Kossler
- Subjects
General Neuroscience ,Neurology (clinical) - Published
- 2022
17. A Guide to Incorporate Augmentative and Alternative Communication Into Functional Communication Training
- Author
-
Ciara L. Ousley and Tracy J. Raulston
- Subjects
Clinical Psychology ,Developmental and Educational Psychology ,Education - Abstract
Children with autism spectrum disorder often display some form of challenging behavior and have complex communication needs. Functional communication training is an evidence-based practice that (a) decreases challenging behavior and (b) increases appropriate communicative behavior. Recent research has demonstrated how using augmentative and alternative communication (i.e., various forms of communication that do not involve vocal speech) can be successfully incorporated into functional communication training interventions. This article introduces a four-step guide on how to incorporate augmentative and alternative communication within functional communication training interventions. Detailed guidelines on how to incorporate augmentative and alternative communication, along with a vignette example, are provided.
- Published
- 2022
18. Associations of historical trauma and racism with health care system distrust and mental health help-seeking propensity among American Indian and Alaska Native college students
- Author
-
Tracy J. Stewart and Vivian M. Gonzalez
- Subjects
Sociology and Political Science ,Social Psychology - Published
- 2023
19. Imaging of Pulmonary Fibrosis: An Update, From the AJR Special Series on Imaging of Fibrosis
- Author
-
Kyung Soo Lee, Joungho Han, Noriaki Wada, Akinori Hata, Ho Yun Lee, ChinA Yi, Takuya Hino, Tracy J. Doyle, Tomas Franquet, and Hiroto Hatabu
- Subjects
Radiology, Nuclear Medicine and imaging ,General Medicine - Published
- 2023
20. Supplementary Data from The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2
- Author
-
Alexander Pietras, Massimo Squatrito, Håkan Axelson, Mattias Belting, Johan Bengzon, Valeria Governa, Fredrik J. Swartling, Tobias Bergström, Elin J. Pietras, Pauline Jeannot, David Lindgren, Kristoffer von Stedingk, Elinn Johansson, Vasiliki Pantazopoulou, Carolina Marques, and Tracy J. Berg
- Abstract
Supplementary Tables
- Published
- 2023
21. Data from Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray
- Author
-
G. Larry Maxwell, J. Carl Barrett, Andrew Berchuck, Tracy J. Litzi, Lou A. Dainty, Gadisetti V.R. Chandramouli, John I. Risinger, and Michael A. Bidus
- Abstract
Purpose: To characterize the gene expression profiles of endometrioid endometrial cancers associated with lymph node metastasis in an effort to identify genes associated with metastatic spread.Experimental Design: Tumors from 41 patients with endometrioid endometrial cancer grossly confined to the uterine cavity were evaluated. Positive lymph nodes were noted in 12 of 41 patients. RNA was analyzed for gene expression using the Affymetrix HG133A and HG133B GeneChip set, representing 45,000 array features covering >28,000 UniGene clusters. Data analysis was done using multidimensional scaling, binary comparison, and hierarchical clustering. Gene expression for several differentially expressed genes was examined using quantitative PCR.Results: Gene expression data was obtained from 30,964 genes that were detected in at least 5% of the cases. Supervised analysis of node-positive versus node-negative cases indicated that 450 genes were significantly differentially expressed between the two classes at P < 0.005, 81 of which were differentially expressed by at least 2-fold at P < 0.005. Overexpressed genes included two cell cycle checkpoint genes, CDC2 and MAD2L1, which have previously been described in association with lymph node metastasis in other cancer types. The ZIC2 zinc finger gene was overexpressed in endometrial cancers with positive nodes versus those with negative nodes.Conclusion: Gene expression profiling of the primary tumors in patients with endometrioid endometrial cancers seems promising for identifying genes associated with lymph node metastasis. Future studies should address whether the status of nodal metastasis can be determined from the expression profiles of preoperative tissue specimens.
- Published
- 2023
22. Supplementary Table S1 from Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray
- Author
-
G. Larry Maxwell, J. Carl Barrett, Andrew Berchuck, Tracy J. Litzi, Lou A. Dainty, Gadisetti V.R. Chandramouli, John I. Risinger, and Michael A. Bidus
- Abstract
Class comparison data
- Published
- 2023
23. Supplementary Figures from The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2
- Author
-
Alexander Pietras, Massimo Squatrito, Håkan Axelson, Mattias Belting, Johan Bengzon, Valeria Governa, Fredrik J. Swartling, Tobias Bergström, Elin J. Pietras, Pauline Jeannot, David Lindgren, Kristoffer von Stedingk, Elinn Johansson, Vasiliki Pantazopoulou, Carolina Marques, and Tracy J. Berg
- Abstract
Supplementary Figures 1-6
- Published
- 2023
24. Data from The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2
- Author
-
Alexander Pietras, Massimo Squatrito, Håkan Axelson, Mattias Belting, Johan Bengzon, Valeria Governa, Fredrik J. Swartling, Tobias Bergström, Elin J. Pietras, Pauline Jeannot, David Lindgren, Kristoffer von Stedingk, Elinn Johansson, Vasiliki Pantazopoulou, Carolina Marques, and Tracy J. Berg
- Abstract
The tumor microenvironment plays an essential role in supporting glioma stemness and radioresistance. Following radiotherapy, recurrent gliomas form in an irradiated microenvironment. Here we report that astrocytes, when pre-irradiated, increase stemness and survival of cocultured glioma cells. Tumor-naïve brains increased reactive astrocytes in response to radiation, and mice subjected to radiation prior to implantation of glioma cells developed more aggressive tumors. Extracellular matrix derived from irradiated astrocytes were found to be a major driver of this phenotype and astrocyte-derived transglutaminase 2 (TGM2) was identified as a promoter of glioma stemness and radioresistance. TGM2 levels increased after radiation in vivo and in recurrent human glioma, and TGM2 inhibitors abrogated glioma stemness and survival. These data suggest that irradiation of the brain results in the formation of a tumor-supportive microenvironment. Therapeutic targeting of radiation-induced, astrocyte-derived extracellular matrix proteins may enhance the efficacy of standard-of-care radiotherapy by reducing stemness in glioma.Significance:These findings presented here indicate that radiotherapy can result in a tumor-supportive microenvironment, the targeting of which may be necessary to overcome tumor cell therapeutic resistance and recurrence.
- Published
- 2023
25. Supplementary Methods from The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2
- Author
-
Alexander Pietras, Massimo Squatrito, Håkan Axelson, Mattias Belting, Johan Bengzon, Valeria Governa, Fredrik J. Swartling, Tobias Bergström, Elin J. Pietras, Pauline Jeannot, David Lindgren, Kristoffer von Stedingk, Elinn Johansson, Vasiliki Pantazopoulou, Carolina Marques, and Tracy J. Berg
- Abstract
Extended experimental details to supplement the main article file methods section
- Published
- 2023
26. Supplementary Tables 1 and 2 from Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium
- Author
-
Eve Roman, Tongzhang Zheng, Yawei Zhang, Sophia S. Wang, Susan L. Slager, Silvia de Sanjosé, Lindsay Morton, Mads Melbye, Mark Liebow, Alex G. Smith, Stephen M. Ansell, Tracy J. Lightfoot, Anne J. Novak, Marc Maynadié, Elizabeth A. Holly, Karin Ekström Smedby, Laura Costas, James R. Cerhan, Paige M. Bracci, Christine F. Skibola, and Eleanor Kane
- Abstract
Supplementary Tables 1 and 2. Joint associations and relative excess risks due to interaction between BMI and cytokine polymorphisms for lymphoid neoplasms
- Published
- 2023
27. Data from Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium
- Author
-
Eve Roman, Tongzhang Zheng, Yawei Zhang, Sophia S. Wang, Susan L. Slager, Silvia de Sanjosé, Lindsay Morton, Mads Melbye, Mark Liebow, Alex G. Smith, Stephen M. Ansell, Tracy J. Lightfoot, Anne J. Novak, Marc Maynadié, Elizabeth A. Holly, Karin Ekström Smedby, Laura Costas, James R. Cerhan, Paige M. Bracci, Christine F. Skibola, and Eleanor Kane
- Abstract
Background: Excess adiposity has been associated with lymphomagenesis, possibly mediated by increased cytokine production causing a chronic inflammatory state. The relationship between obesity, cytokine polymorphisms, and selected mature B-cell neoplasms is reported.Method: Data on 4,979 cases and 4,752 controls from nine American/European studies from the InterLymph consortium (1988–2008) were pooled. For diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), joint associations of body mass index (from self-reported height and weight) and 12 polymorphisms in cytokines IL1A (rs1800587), IL1B (rs16944, rs1143627), IL1RN (rs454078), IL2 (rs2069762), IL6 (rs1800795, rs1800797), IL10 (rs1800890, rs1800896), TNF (rs1800629), LTA (rs909253), and CARD15 (rs2066847) were investigated using unconditional logistic regression. BMI-polymorphism interaction effects were estimated using the relative excess risk due to interaction (RERI).Results: Obesity (BMI ≥ 30 kg/m2) was associated with DLBCL risk [OR = 1.33; 95% confidence interval (CI), 1.02–1.73], as was TNF-308GA+AA (OR = 1.24; 95% CI, 1.07–1.44). Together, being obese and TNF-308GA+AA increased DLBCL risk almost 2-fold relative to those of normal weight and TNF-308GG (OR = 1.93; 95% CI, 1.27–2.94), with a RERI of 0.41 (95% CI, −0.05–0.84; Pinteraction = 0.13). For FL and CLL/SLL, no associations with obesity or TNF-308GA+AA, either singly or jointly, were observed. No evidence of interactions between obesity and the other polymorphisms were detected.Conclusions: Our results suggest that cytokine polymorphisms do not generally interact with BMI to increase lymphoma risk but obesity and TNF-308GA+AA may interact to increase DLBCL risk.Impact: Studies using better measures of adiposity are needed to further investigate the interactions between obesity and TNF-308G>A in the pathogenesis of lymphoma. Cancer Epidemiol Biomarkers Prev; 24(7); 1061–70. ©2015 AACR.
- Published
- 2023
28. Supplementary Table S2 from Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray
- Author
-
G. Larry Maxwell, J. Carl Barrett, Andrew Berchuck, Tracy J. Litzi, Lou A. Dainty, Gadisetti V.R. Chandramouli, John I. Risinger, and Michael A. Bidus
- Abstract
EASE data
- Published
- 2023
29. 2B-Alert App 2.0: personalized caffeine recommendations for optimal alertness
- Author
-
Francisco G Vital-Lopez, Tracy J Doty, Ian Anlap, William D S Killgore, and Jaques Reifman
- Subjects
Physiology (medical) ,Neurology (clinical) - Abstract
Study Objectives If properly consumed, caffeine can safely and effectively mitigate the effects of sleep loss on alertness. However, there are no tools to determine the amount and time to consume caffeine to maximize its effectiveness. Here, we extended the capabilities of the 2B-Alert app, a unique smartphone application that learns an individual’s trait-like response to sleep loss, to provide personalized caffeine recommendations to optimize alertness. Methods We prospectively validated 2B-Alert’s capabilities in a 62-hour total sleep deprivation study in which 21 participants used the app to measure their alertness throughout the study via the psychomotor vigilance test (PVT). Using PVT data collected during the first 36 hours of the sleep challenge, the app learned the participant’s sleep-loss response and provided personalized caffeine recommendations so that each participant would sustain alertness at a pre-specified target level (mean response time of 270 milliseconds) during a 6-hour period starting at 44 hours of wakefulness, using the least amount of caffeine possible. Starting at 42 hours, participants consumed 0 to 800 mg of caffeine, per the app recommendation. Results 2B-Alert recommended no caffeine to five participants, 100–400 mg to 11 participants, and 500–800 mg to five participants. Regardless of the consumed amount, participants sustained the target alertness level ~80% of the time. Conclusions 2B-Alert automatically learns an individual’s phenotype and provides personalized caffeine recommendations in real time so that individuals achieve a desired alertness level regardless of their sleep-loss susceptibility.
- Published
- 2023
30. Pelagic microplastics in the North Pacific Subtropical Gyre: A prevalent anthropogenic component of the particulate organic carbon pool
- Author
-
Shiye Zhao, Tracy J Mincer, Laurent Lebreton, and Matthias Egger
- Abstract
Due to its ever-increasing ocean inputs, fossil-based microplastics (MP) comprise a considerable constituent in the particulate organic carbon (POC) pool, which is instrumental in ocean biogeochemical cycling. Their distribution within the oceanic water column and the underpinning processes, however, remain unclear. Here we show that MP prevail throughout the water column of the eastern North Pacific Subtropical Gyre, comprising 334 #/m3 (84.5% of plastic particles
- Published
- 2023
31. Preclinical or subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences
- Author
-
Elizabeth R Volkmann, Jeffrey A Sparks, Anna-Maria Hoffmann-Vold, Tracy J Doyle, Paul Emery, and Philippe Dieudé
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy - Published
- 2023
32. Imbricated shell sculpture in benthic bivalves
- Author
-
Geerat J. Vermeij and Tracy J. Thomson
- Subjects
Animal Science and Zoology ,Developmental Biology - Published
- 2023
33. Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient
- Author
-
Sjanna B Besteman, Emily Phung, Henriette H M Raeven, Gimano D Amatngalim, Matevž Rumpret, Juliet Crabtree, Rutger M Schepp, Lisa W Rodenburg, Susanna G Siemonsma, Nile Verleur, Rianne van Slooten, Karen Duran, Gijs W van Haaften, Jeffrey M Beekman, Lauren A Chang, Linde Meyaard, Tjomme van der Bruggen, Guy A M Berbers, Nicole Derksen, Stefan Nierkens, Kaitlyn M Morabito, Tracy J Ruckwardt, Evelyn A Kurt-Jones, Douglas Golenbock, Barney S Graham, and Louis J Bont
- Subjects
Infectious Diseases ,Toll-like receptor ,Respiratory Syncytial Virus, Human ,monocyte ,Leukocytes, Mononuclear ,Lipopolysaccharide Receptors ,Cytokines ,Humans ,Immunology and Allergy ,Respiratory Syncytial Virus Infections ,Respiratory syncytial virus ,CD14 ,epithelium - Abstract
Background Recurrent respiratory syncytial virus (RSV) infection requiring hospitalization is rare and the underlying mechanism is unknown. We aimed to determine the role of CD14-mediated immunity in the pathogenesis of recurrent RSV infection. Methods We performed genotyping and longitudinal immunophenotyping of the first patient with a genetic CD14 deficiency who developed recurrent RSV infection. We analyzed gene expression profiles and interleukin (IL)-6 production by patient peripheral blood mononuclear cells in response to RSV pre- and post-fusion (F) protein. We generated CD14-deficient human nasal epithelial cells cultured at air-liquid interface (HNEC-ALI) of patient-derived cells and after CRISPR-based gene editing of control cells. We analyzed viral replication upon RSV infection. Results Sanger sequencing revealed a homozygous single-nucleotide deletion in CD14, resulting in absence of the CD14 protein in the index patient. In vitro, viral replication was similar in wild-type and CD14−/− HNEC-ALI. Loss of immune cell CD14 led to impaired cytokine and chemokine responses to RSV pre- and post-F protein, characterized by absence of IL-6 production. Conclusions We report an association of recurrent RSV bronchiolitis with a loss of CD14 function in immune cells. Lack of CD14 function led to defective immune responses to RSV pre- and post-F protein without a change in viral replication.
- Published
- 2022
34. Prospective randomized trial of metal versus resorbable plates in surgical stabilization of rib fractures
- Author
-
Dennis W, Ashley, Dudley B, Christie, Eric L, Long, Rajani, Adiga, Tracy J, Johns, Josephine, Fabico-Dulin, and Anne, Montgomery
- Subjects
Narcotics ,Fracture Fixation, Internal ,Rib Fractures ,Quality of Life ,Humans ,Pain ,Surgery ,Prospective Studies ,Critical Care and Intensive Care Medicine - Abstract
Surgical stabilization of rib fractures has gained popularity as both metal and resorbable plates have been approved for fracture repair. Is there a difference between metal and resorbable plate rib fixation regarding rib fracture alignment, control of pain, and quality-of-life (QOL) scores (Rand SF-36 survey)?Eligible patients (pts) included 18 years or older with one or more of the following: flail chest, one or more bicortical displaced fractures (3-10), nondisplaced fractures with failure of medical management. Patients were randomized to either metal or resorbable plate fixation. Primary outcome was fracture alignment. Secondary outcomes were pain scores, opioid use, and QOL scores.Thirty pts were randomized (15 metal/15 resorbable). Total ribs plated 167 (88 metal/79 resorbable). Patients with rib displacement at day of discharge (DOD) metal 0/14 (one pt died, not from plating) versus resorbable 9/15 or 60% ( p = 0.001). Ribs displaced at DOD metal 0/88 versus resorbable 22/79 or 28% ( p0.001), 48% in posterior location. Patients with increased rib displacement 3 months to 6 months: metal, 0/11 versus resorbable, 3/9 or 33% ( p = 0.043). Ribs with increased displacement 3 months to 6 months metal 0 of 67 versus resorbable 6 of 49 or 12.2% ( p0.004). Pain scores and narcotic use at postoperative Days 1, 2, 3, DOD, 2 weeks, 3 months and 6 months showed no statistically significant difference between groups. QOL scores were also similar at 3 months and 6 months. Trauma recidivism in outpatient period resulted in fracture of resorbable plates in two pts requiring a second surgery.Metal plates provided better initial alignment with no displacement over time. Clinical outcomes were similar regarding pain, narcotic use, and QOL scores. Routine use of resorbable plates for posterior rib fractures is not warranted. Lateral repairs were technically most feasible for using resorbable plates but still resulted in significant displacement. Resorbable plates may not maintain rib alignment when exposed to subsequent injury.Therapeutic/Care Management; Level II.
- Published
- 2022
35. To Tranexamic Acid or Not to Tranexamic Acid? Accuracy of Antifibrinolytic Administration at Altitude
- Author
-
Joseph DeVitis, Aaron Ziegler, Chad Barnhart, Alistair Chapman, Cathryn Chadwick, Matthew Dull, Charles Gibson, Tracy J. Koehler, Alan T. Davis, Gaby Iskander, Steffen Pounders, Laura Krech, and Chelsea Starr Fisk
- Subjects
Adult ,Tranexamic Acid ,Altitude ,Emergency Medicine ,Humans ,Wounds and Injuries ,Hemorrhage ,Emergency Nursing ,Antifibrinolytic Agents ,Retrospective Studies - Abstract
Tranexamic acid (TXA) has demonstrated a reduction in all-cause mortality in trauma patients with hemorrhage. Administering TXA in the prehospital setting presents unique challenges because the identification of bleeding is based on clinical suspicion without advanced imaging or diagnostic tools. The objective of this study was to examine whether prehospital suspicion of bleeding is validated by in-hospital computed tomographic imaging and examination and to determine if patients received TXA in the absence of hemorrhage. The study was conducted at a level 1 trauma center supported by air medical transport services.This is a retrospective cohort study examining 88 trauma patients receiving prehospital TXA to treat suspected hemorrhage. Adult trauma patients who received TXA during the study period and were transported to our level 1 trauma center were included. A panel of trauma surgeons reviewed CT imaging and examination findings to retrospectively identify significant hemorrhage.Forty-three percent of patients who received TXA during air medical transport did not have confirmed hemorrhage upon arrival.TXA was given to a significant number of patients who did not have confirmed hemorrhage upon arrival. We recommend that institutions using TXA perform this internal validation to ensure they are accurately identifying hemorrhage in the prehospital setting.
- Published
- 2022
36. Twice-Modulated Light in Fourier Transform Infrared (FT-IR) Spectrometers from Reflective Samples: Avoiding Distorted Intensity Values
- Author
-
Timothy J. Johnson, Tracy J. Baker, Ashley M. Bradley, Michael O. Yokosuk, and Tanya L. Myers
- Subjects
Instrumentation ,Spectroscopy - Abstract
We document an artifact associated with the back reflection from samples or sampling accessories in Fourier transform spectrometers. Samples oriented normal to the incoming modulated beam can reflect light back to the interferometer and this light (the percentage dependent on the sample’s refractive index) is modulated by the interferometer a second time resulting in light erroneously appearing at twice its true frequency. The phenomenon occurs across the spectrum but is most apparent when positive-going narrow absorption peaks at 1 f display as negative-going peaks at 2 f. We have redressed the artifact by implementing a rotation stage directly beneath the sample holder: As the stage is rotated through small angles relative to beam normal, the back-reflected light does not enter the interferometer and the artifact disappears. The observation is relevant to several IR sampling methods: gas/liquid cells, alkali halide pellets, reflectance accessories, etc.
- Published
- 2022
37. Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine
- Author
-
Tracy J. Lu and Christopher N. Ta
- Subjects
Ophthalmology ,viruses ,virus diseases - Abstract
We present a case of herpes zoster keratitis reactivation shortly following the Shingrix vaccine. In our patient, reactivation of herpes zoster keratitis occurred a few weeks following the herpes zoster subunit (HZ/su) vaccine. The development of herpes zoster ophthalmicus following HZ/su is exceedingly rare, with only one prior reported case found in the literature. Reporting of this potential correlation is important in understanding the full risks of vaccines and can help elucidate the etiology of such responses.
- Published
- 2022
38. Advanced brain age in deployment-related traumatic brain injury: A LIMBIC-CENC neuroimaging study
- Author
-
Emily L Dennis, Brian A Taylor, Mary R Newsome, Maya Troyanskaya, Tracy J Abildskov, Aaron M Betts, Erin D Bigler, James Cole, Nicholas Davenport, Timothy Duncan, Jessica Gill, Vivian Guedes, Sidney R Hinds, Elizabeth S Hovenden, Kimbra Kenney, Mary Jo Pugh, Randall S Scheibel, Pashtun-Poh Shahim, Robert Shih, William C Walker, J. Kent Werner, Gerald E York, David X Cifu, David F Tate, and Elisabeth A Wilde
- Subjects
Adult ,Male ,Neuroscience (miscellaneous) ,Brain ,Neuroimaging ,Article ,United States ,Stress Disorders, Post-Traumatic ,Alcoholism ,Cross-Sectional Studies ,Military Personnel ,Brain Injuries, Traumatic ,Developmental and Educational Psychology ,Humans ,Female ,Neurology (clinical) ,Brain Concussion ,Veterans - Abstract
To determine if history of mild traumatic brain injury (mTBI) is associated with advanced or accelerated brain aging among the United States (US) military Service Members and Veterans. Eight hundred and twenty-two participants (mean age = 40.4 years, 714 male/108 female) underwent MRI sessions at eight sites across the US. Two hundred and one participants completed a follow-up scan between five months and four years later. Predicted brain ages were calculated using T1-weighted MRIs and then compared with chronological ages to generate an Age Deviation Score for cross-sectional analyses and an Interval Deviation Score for longitudinal analyses. Participants also completed a neuropsychological battery, including measures of both cognitive functioning and psychological health. In cross-sectional analyses, males with a history of deployment-related mTBI showed advanced brain age compared to those without (t(884) = 2.1, p = .038), while this association was not significant in females. In follow-up analyses of the male participants, severity of posttraumatic stress disorder (PTSD), depression symptoms, and alcohol misuse were also associated with advanced brain age. History of deployment-related mTBI, severity of PTSD and depression symptoms, and alcohol misuse are associated with advanced brain aging in male US military Service Members and Veterans.
- Published
- 2022
39. The Impact of a Neurocritical Care and Neuropalliative Collaboration on Intensive Care Unit Outcomes
- Author
-
Andersen J. Shemme, Joel N. Phillips, Rafael Bloise, Tracy J. Koehler, Philip B. Gorelick, and Brandon A. Francis
- Subjects
Cohort Studies ,Hospitalization ,Intensive Care Units ,Humans ,Hospital Mortality ,General Medicine ,Length of Stay ,Retrospective Studies - Abstract
Background: Neurocritical care (NCC) and neuropalliative care (NPC) clinicians provide care in specialized intensive care units (ICU). There is a paucity of data regarding the impact of NCC and NPC collaboration in smaller, community-focused settings. Objective: To determine the clinical impact of introducing a NCC/NPC collaborative model in a mixed ICU community-based teaching hospital. Design: Retrospective pre/post cohort study. Subjects: Patients ≥18 years of age admitted to the ICU who received neurology and palliative care consultations between September 1, 2015 and August 31, 2017 at a 300 bed community-focused hospital were included. Intervention: The addition of a NCC/NPC collaborative model took place in September of 2016. The time periods before (9/1/2015 to 8/31/2016) and after (9/1/2016 to 8/31/2017) the addition were compared. Results: A total of 274 admissions (pre: 130, post: 144) were included. There were significantly more NCC consultations provided in the post-period (44.6% vs 57.6%; P = .03). NPC consultation increased (55.4% vs 66.7%; P = .056) Median LOS was significantly shorter after implementation of the collaborative model (11 vs 8 days; P = .01). Median ICU LOS was also shorter by 1 ICU-day in the post-period, though this was not statistically significant ( P = .23). Mortality rates were similar ( P = .95). Conclusions: Our findings suggest NCC/NPC collaboration in a community-focused teaching hospital was associated with more NCC consultations, as well as shorter LOS without increasing mortality. These data highlight the importance of supporting collaborative models of care in community settings. Further research is warranted.
- Published
- 2022
40. Does social support moderate the relationship between gender minority stress and suicide within a sample of transgender and gender diverse people?
- Author
-
Sarah E. Rimmer, Tracy J. Cohn, Sarah L. Hastings, Jenessa C. Steele, and Charles Woods
- Subjects
Psychiatry and Mental health ,Clinical Psychology ,Health (social science) - Published
- 2022
41. Streamlined alpha‐amylase assays for wheat preharvest sprouting and late maturity alpha‐amylase detection
- Author
-
Amber L. Hauvermale, Rehana S. Parveen, Tracy J. Harris, Keiko M. Tuttle, Galina Mikhaylenko, Sindhu Nair, Andrew G. McCubbin, Michael O. Pumphrey, and Camille M. Steber
- Subjects
Soil Science ,Plant Science ,Agricultural and Biological Sciences (miscellaneous) - Published
- 2023
42. Screening for preclinical parenchymal lung disease in rheumatoid arthritis
- Author
-
Anthony J Esposito, Jeffrey A Sparks, Ritu R Gill, Hiroto Hatabu, Eric J Schmidlin, Partha V Hota, Sergio Poli, Elaine A Fletcher, Wesley Xiong, Michelle L Frits, Christine K Iannaccone, Maria Prado, Alessandra Zaccardelli, Allison Marshall, Paul F Dellaripa, Michael E Weinblatt, Nancy A Shadick, Ivan O Rosas, and Tracy J Doyle
- Subjects
Arthritis, Rheumatoid ,Emphysema ,Rheumatology ,Humans ,Pharmacology (medical) ,Prospective Studies ,Clinical Science ,respiratory system ,Lung Diseases, Interstitial ,Lung ,respiratory tract diseases - Abstract
Objectives Pulmonary disease is a common extraarticular manifestation of RA associated with increased morbidity and mortality. No current strategies exist for screening this at-risk population for parenchymal lung disease, including emphysema and interstitial lung disease (ILD). Methods RA patients without a diagnosis of ILD or chronic obstructive pulmonary disease underwent prospective and comprehensive clinical, laboratory, functional and radiological evaluations. High resolution CT (HRCT) scans were scored for preclinical emphysema and preclinical ILD and evaluated for other abnormalities. Results Pulmonary imaging and/or functional abnormalities were identified in 78 (74%) of 106 subjects; 45% had preclinical parenchymal lung disease. These individuals were older with lower diffusion capacity but had similar smoking histories compared with no disease. Preclinical emphysema (36%), the most commonly detected abnormality, was associated with older age, higher anti-cyclic citrullinated peptide antibody titres and diffusion abnormalities. A significant proportion of preclinical emphysema occurred among never smokers (47%) with a predominantly panlobular pattern. Preclinical ILD (15%) was not associated with clinical, laboratory or functional measures. Conclusion We identified a high prevalence of undiagnosed preclinical parenchymal lung disease in RA driven primarily by isolated emphysema, suggesting that it may be a prevalent and previously unrecognized pulmonary manifestation of RA, even among never smokers. As clinical, laboratory and functional evaluations did not adequately identify preclinical parenchymal abnormalities, HRCT may be the most effective screening modality currently available for patients with RA.
- Published
- 2021
43. Effects of a Novel Rotator Cuff Rehabilitation Device on Shoulder Strength and Function
- Author
-
Lindsay R. Abrams, Nicole A. Galluzzo, Shou-An Liu, Jamie A. Savitzky, John P. Handrakis, Tracy J. Protosow, Samantha P. Ostrow, and Karen Friel
- Subjects
Adult ,Male ,Shoulder ,medicine.medical_specialty ,Rehabilitation ,Shoulder Joint ,business.industry ,medicine.medical_treatment ,Physical Therapy, Sports Therapy and Rehabilitation ,General Medicine ,Function (mathematics) ,Upper Extremity ,Rotator Cuff ,Physical medicine and rehabilitation ,medicine.anatomical_structure ,medicine ,Humans ,Female ,Orthopedics and Sports Medicine ,Rotator cuff ,Range of Motion, Articular ,business - Abstract
Savitzky, JA, Abrams, LR, Galluzzo, NA, Ostrow, SP, Protosow, TJ, Liu, SA, Handrakis, JP, and Friel, K. Effects of a novel rotator cuff rehabilitation device on shoulder strength and function. J Strength Cond Res 35(12): 3355-3363, 2021-The glenohumeral joint, a multiaxial ball and socket joint, has inherent instability counterbalanced by the muscular stability of the rotator cuff (RC) and connective tissue. Exercise has been shown to alleviate pain and disability arising from degenerative changes of the RC due to overuse, trauma, or poor posture. This study compared the training effects of ShoulderSphere (SS), an innovative device that uses resistance to centrifugal force, to TheraBand (TB), a traditional device that uses resistance to elasticity. Thirty-five healthy male and female adults (24.2 ± 2.4 years) were randomized into 3 groups: SS, TB, and control. Five outcomes were assessed before and after the twice-weekly, 6-week intervention phase: strength (shoulder flexion [Fx], extension [Ext], external rotation [ER], and internal rotation [IR]), proprioception (6 positions), posterior shoulder endurance (ShEnd), stability (Upper Quarter Y-Balance Test [YBal] (superolateral [YBalSup], medial [YBalMed], and inferolateral [YBalInf]), and power (seated shot put [ShtPt]). Data were analyzed using a 3 (group: SS, TB, and control) × 2 (time: pre and post) generalized estimating equation. Analyses demonstrated a main effect of time for all strength motions (p0.01): YBalInf (p0.0001), ShtPt (p0.05), and ShEnd (p0.0001) but no interaction effects of group × time. There were no main or interaction effects for proprioception. Both SS and TB groups had significant within-group increases in Ext, IR, YBalInf, and ShEnd. Only the SS group had significant increases in ER, Fx, and ShtPt. ShoulderSphere demonstrated comparable conditioning effects with TB and may afford additional strength gains in Fx and ER, and power. ShoulderSphere should be considered a viable alternative in RC conditioning.
- Published
- 2021
44. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process
- Author
-
Joshua J Solomon, Vibeke Strand, Chester V. Oddis, Leticia Kawano-Dourado, Tracy J. Doyle, Jeffrey A. Sparks, Kevin K. Brown, Susanna Proudman, Athol U. Wells, Donald P. Tashkin, Dorcas E. Beaton, Dinesh Khanna, Whitney Townsend, Lara J Maxwell, Shaney L Barratt, James R. Seibold, Paul F. Dellaripa, Robert Vassallo, David Roofeh, Eric L. Matteson, Thomas Leonard, and Robin Christensen
- Subjects
medicine.medical_specialty ,Population ,Outcome measures ,Article ,law.invention ,Core set ,FEV1/FVC ratio ,Rheumatology ,Randomized controlled trial ,DLCO ,law ,Forced vital capacity ,Humans ,Medicine ,education ,Lung ,education.field_of_study ,Scleroderma, Systemic ,business.industry ,OMERACT ,Reproducibility of Results ,Construct validity ,respiratory system ,Diffusion capacity of carbon monoxide ,Respiratory Function Tests ,respiratory tract diseases ,Clinical trial ,Anesthesiology and Pain Medicine ,Systematic review ,Systemic sclerosis interstitial lung disease ,Physical therapy ,Observational study ,Lung Diseases, Interstitial ,business - Abstract
Objective The Outcome Measures in Rheumatology (OMERACT) is a research organization focused on improving health care outcomes for patients with autoimmune and musculoskeletal diseases. The Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) Working Group on Lung Physiology is a group within OMERACT charged with identifying outcome measures that should be implemented in studies of patients with CTD-ILD. The OMERACT Filter 2.1 is an evidence-based algorithm used to identify outcome measures that are truthful, feasible, and able to discriminate between groups of interest. Our objective was to summate evidence (published literature, key opinion leader input, patient perspectives) that would influence the CTD-ILD Working Group's vote to accept or reject the use of two measures of lung physiology, the forced vital capacity (FVC) and the diffusion capacity of carbon monoxide (DLco) for use in randomized controlled trials (RTCs) and longitudinal observational studies (LOSs) involving patients with systemic sclerosis associated ILD (SSc-ILD). Methods Patient Research Partners (those afflicted with SSc-ILD) and the CTD-ILD Working Group on Lung Physiology were polled to assess their opinion on the FVC and DLco in terms of feasibility; the CTD-ILD Working Group was also queried on these instruments’ face and content validity. We then conducted a systematic literature review to identify articles in the SSc-ILD population that assessed the following measurement properties of FVC and DLco: (1) construct validity, (2) test-retest reliability, (3) longitudinal construct validity, (4) clinical trial discrimination/sensitivity to detect change in clinical trials, and (5) thresholds of meaning. Results were summarized in a Summary of Measurement Properties (SOMP) table for each instrument. OMERACT CTD-ILD Working Group members discussed and voted on the strength of evidence supporting these two instruments and voted to endorse, provisionally endorse, or not endorse either instrument. Results Forty Patient Research Partners reported these two measures are feasible (are not an unnecessary burden or represent an infeasible longitudinal assessment of their disease). A majority of the 18 CTD-ILD Working Group members voted that both the FVC and DLco are feasible and have face and content validity. The systematic literature review returned 1,447 non-duplicated articles, of which 177 met eligibility for full text review. Forty-eight studies (13 RCTs, 35 LOSs) were included in the qualitative analysis. The FVC SOMP table revealed high quality, consistent data with evidence of good performance for all five measurement properties, suggesting requisite published evidence to proceed with endorsement. The DLco SOMP table showed a lack of data to support test-retest reliability and inadequate evidence to support clinical trial discrimination. There was unanimous agreement (15 [100%]) among voting CTD-ILD Working Group members to endorse the FVC as an instrument for lung physiology in RCTs and LOSs in SSc-ILD. Based on currently available evidence, DLco did not meet the OMERACT criteria and is not recommended for use in RCTs to represent lung physiology of SSc-ILD. The OMERACT Technical Advisory Group agreed with these decisions. Conclusion The OMERACT Filter 2.1 was successfully applied to the domain of lung physiology in patients with SSc-ILD. The FVC was endorsed for use in RCTs and LOSs based on the Working Group's vote; DLco was not endorsed.
- Published
- 2021
45. A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine
- Author
-
Lauren A. Chang, Emily Phung, Michelle C. Crank, Kaitlyn M. Morabito, Tonya Villafana, Filip Dubovsky, Judith Falloon, Mark T. Esser, Bob C. Lin, Grace L. Chen, Barney S. Graham, and Tracy J. Ruckwardt
- Subjects
Respiratory Syncytial Virus, Human ,Vaccines, Subunit ,Respiratory Syncytial Virus Vaccines ,Humans ,General Medicine ,Respiratory Syncytial Virus Infections ,Antigens ,Antibodies, Viral ,Viral Fusion Proteins ,Antibodies, Neutralizing - Abstract
There is currently no licensed vaccine for respiratory syncytial virus (RSV). Here, we assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510 [postfusion (post-F)] vaccine clinical trials. We compared the magnitude and quality of the serological and B cell responses across time points and vaccines. We measured RSV A and B neutralization, F-binding immunoglobulin G titers, and competition assays at week 0 (before vaccination) and week 4 (after vaccination) to evaluate antibody specificity and potency. To compare B cell specificity and activation, we used pre-F and post-F probes in tandem with a 17-color immunophenotyping flow cytometry panel at week 0 (before vaccination) and week 1 (after vaccination). Our data demonstrate that both DS-Cav1 and MEDI7510 vaccination robustly elicit F-specific antibodies and B cells, but DS-Cav1 elicited antibodies that more potently neutralized both RSV A and B. The superior potency was mediated by antibodies that bind antigenic sites on the apex of pre-F that are not present on post-F. In the memory (CD27 + ) B cell compartment, vaccination with DS-Cav1 or MEDI7510 elicited B cells with different epitope specificities. B cells preferentially binding the pre-F probe were activated in DS-Cav1–vaccinated participants but not in MEDI7510-vaccinated participants. Our findings emphasize the importance of using pre-F as an immunogen in humans because of its deterministic role in eliciting highly potent neutralizing antibodies and memory B cells.
- Published
- 2022
46. Prevalence and mortality associations of interstitial lung abnormalities in rheumatoid arthritis within a multicenter prospective cohort of smokers
- Author
-
Gregory C McDermott, Keigo Hayashi, Kazuki Yoshida, Matthew Moll, Michael H Cho, Tracy J Doyle, Gregory L Kinney, Paul F Dellaripa, Rachel K Putman, Raul San Jose Estepar, Akinori Hata, Takuya Hino, Tomoyuki Hida, Masahiro Yanagawa, Mizuki Nishino, George Washko, Elizabeth Regan, Hiroto Hatabu, Gary M Hunninghake, Edwin K Silverman, and Jeffrey A Sparks
- Abstract
ObjectivesInvestigate the prevalence and mortality impact of interstitial lung abnormalities (ILA) in rheumatoid arthritis (RA) and non-RA comparators.MethodsWe analyzed associations between ILA, RA, and mortality in COPDGene, a multicenter prospective cohort study of current or former smokers, excluding known interstitial lung disease (ILD) or bronchiectasis. All participants had research chest high-resolution computed tomography (HRCT) reviewed by a sequential reading method to classify ILA as present, indeterminate, or absent as well as fibrotic or nonfibrotic ILA subtype. RA cases were identified by self-report RA and DMARD use; non-RA comparators had neither an RA diagnosis nor used DMARDs. We examined the association and mortality risk of RA and ILA using multivariable logistic regression and Cox regression.ResultsWe identified 83 RA cases and 8725 non-RA comparators with HRCT performed for research purposes. ILA prevalence was 16.9% in RA cases and 5.0% in non-RA comparators. After adjusting for potential confounders including genetics, smoking, and other lifestyle factors, ILA were more common among those with RA compared to non-RA (OR 4.76 95%CI 2.54 to 8.92). RA with ILA or indeterminate for ILA was associated with higher mortality compared to non-RA without ILA (HR 3.16, 95%CI 2.11 to 4.74) and RA cases without ILA (HR 3.02, 95%CI 1.36 to 6.75).ConclusionsRA was associated with ILA and this persisted after adjustment for smoking and genetic/lifestyle risk factors. RA with ILA in chronic heavy smokers had 3-fold increased mortality, emphasizing the importance of further screening and treatment strategies for subclinical ILD in RA.KEY MESSAGESWhat is already known on this topicUp to a third of patients with rheumatoid arthritis (RA) may have evidence of subclinical interstitial lung abnormalities on computed tomography (CT) scans of the chest.Cigarette smoking and theMUC5Bpromoter variant are known risk factors for RA-associated interstitial lung disease.What this study addsWe found that 17% of RA patients had subclinical interstitial lung abnormalities. RA had 4-fold higher odds of interstitial lung abnormalities than non-RA comparators, adjusted for smoking, theMUC5Bpromoter variant, and other factors.Participants with RA and no interstitial lung abnormalities were not at increased mortality risk while those with interstitial lung abnormalities or indeterminate for ILA had a three-fold increased risk of mortality compared to RA and non-RA patients without interstitial lung abnormalities.How this study might affect research, practice or policyThe presence of subclinical interstitial lung abnormalities confers significant mortality risk in RA and emphasizes the need to establish the clinical utility of screening, prevention, and treatment strategies targeting subclinical lung disease.
- Published
- 2022
47. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones
- Author
-
Noemia S. Lima, Maryam Musayev, Timothy S. Johnston, Danielle A. Wagner, Amy R. Henry, Lingshu Wang, Eun Sung Yang, Yi Zhang, Kevina Birungi, Walker P. Black, Sijy O’Dell, Stephen D. Schmidt, Damee Moon, Cynthia G. Lorang, Bingchun Zhao, Man Chen, Kristin L. Boswell, Jesmine Roberts-Torres, Rachel L. Davis, Lowrey Peyton, Sandeep R. Narpala, Sarah O’Connell, Leonid Serebryannyy, Jennifer Wang, Alexander Schrager, Chloe Adrienna Talana, Geoffrey Shimberg, Kwanyee Leung, Wei Shi, Rawan Khashab, Asaf Biber, Tal Zilberman, Joshua Rhein, Sara Vetter, Afeefa Ahmed, Laura Novik, Alicia Widge, Ingelise Gordon, Mercy Guech, I-Ting Teng, Emily Phung, Tracy J. Ruckwardt, Amarendra Pegu, John Misasi, Nicole A. Doria-Rose, Martin Gaudinski, Richard A. Koup, Peter D. Kwong, Adrian B. McDermott, Sharon Amit, Timothy W. Schacker, Itzchak Levy, John R. Mascola, Nancy J. Sullivan, Chaim A. Schramm, and Daniel C. Douek
- Subjects
Multidisciplinary ,SARS-CoV-2 ,Immunoglobulin Variable Region ,COVID-19 ,Antibodies, Monoclonal ,General Physics and Astronomy ,General Chemistry ,Antibodies, Viral ,Antibodies, Neutralizing ,General Biochemistry, Genetics and Molecular Biology ,Clone Cells ,Epitopes ,Spike Glycoprotein, Coronavirus ,Humans - Abstract
An important consequence of infection with a SARS-CoV-2 variant is protective humoral immunity against other variants. However, the basis for such cross-protection at the molecular level is incompletely understood. Here, we characterized the repertoire and epitope specificity of antibodies elicited by infection with the Beta, Gamma and WA1 ancestral variants and assessed their cross-reactivity to these and the more recent Delta and Omicron variants. We developed a method to obtain immunoglobulin sequences with concurrent rapid production and functional assessment of monoclonal antibodies from hundreds of single B cells sorted by flow cytometry. Infection with any variant elicited similar cross-binding antibody responses exhibiting a conserved hierarchy of epitope immunodominance. Furthermore, convergent V gene usage and similar public B cell clones were elicited regardless of infecting variant. These convergent responses despite antigenic variation may account for the continued efficacy of vaccines based on a single ancestral variant.
- Published
- 2022
48. Morphological relationships between vertebrate claw unguals and sheaths and the functional morphology of these structures
- Author
-
Tracy J. Thomson and Ryosuke Motani
- Subjects
Birds ,Mammals ,Hoof and Claw ,Animals ,Animal Science and Zoology ,Developmental Biology - Abstract
The link between claw morphology and function has been historically difficult to quantify, analyze, and interpret. A confounding factor is the ambiguous morphological relationship between the ungual and the sheath and whether one structure or the other is more useful for inferring function from morphology. In this study, the functional morphology of vertebrate claws is analyzed using sheath and ungual measurements taken from modern claw specimens spanning birds and mammals. Claw measurements were chosen for their potential biomechanical significance and a revised, expanded categorization of claw function is used. When corresponding claw measurements from the ungual and sheath are compared independently, some features are highly correlated whereas others are not. A principal component analysis of the claw measurements reveals that some of the morphological disparity is related to functional differences; however, different functional categories are not clearly separated based solely on morphology. A linear discriminant analysis incorporating a supervised dimensionality reduction method (J-function) successfully classifies 94.52% of the claw specimens to their documented functional categories. When the posterior probabilities of each classification are examined, and the next highest probabilities are considered, the analysis can successfully classify 98.63% of the claw specimens. Sheath measurements perform better than ungual measurements but combining measurements from both structures perform better than considering either structure individually. Both structures contribute valuable morphological information when it comes to inferring claw function from morphology.
- Published
- 2022
49. Association of Sinusitis and Upper Respiratory Tract Diseases With Incident Rheumatoid Arthritis: A Case-control Study
- Author
-
Elena Losina, John M. Davis, Weixing Huang, Cynthia S. Crowson, Alessandra Zaccardelli, Vanessa L. Kronzer, Tracy J. Doyle, Jeffrey A. Sparks, and Robert Vassallo
- Subjects
Male ,medicine.medical_specialty ,Immunology ,Acute Pharyngitis ,Article ,Arthritis, Rheumatoid ,Rheumatology ,Rheumatoid Factor ,Risk Factors ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Rheumatoid factor ,Sinusitis ,Asthma ,business.industry ,Smoking ,Case-control study ,Chronic sinusitis ,Odds ratio ,Middle Aged ,medicine.disease ,Pharyngitis ,Case-Control Studies ,Female ,medicine.symptom ,business - Abstract
ObjectiveWe aimed to determine whether specific respiratory tract diseases are associated with increased rheumatoid arthritis (RA) risk.MethodsThis case-control study within the Mass General Brigham Biobank matched newly diagnosed RA cases to 3 controls on age, sex, and electronic health record history. We identified RA using a validated algorithm and confirmed by medical record review. Respiratory tract disease exposure required 1 inpatient or 2 outpatient codes at least 2 years before the index date of RA clinical diagnosis or matched date. Logistic regression models calculated ORs for RA with 95% CIs, adjusting for confounders. We then stratified by serostatus (“seropositive” was positive rheumatoid factor and/or anticitrullinated protein antibodies) and smoking.ResultsWe identified 741 RA cases and 2223 controls (both median age 55, 76% female). Acute sinusitis (OR 1.61, 95% CI 1.05–2.45), chronic sinusitis (OR 2.16, 95% CI 1.39–3.35), and asthma (OR 1.39, 95% CI 1.03–1.87) were associated with increased risk of RA. Acute respiratory tract disease burden during the preindex exposure period was also associated with increased RA risk (OR 1.30 per 10 codes, 95% CI 1.08–1.55). Acute pharyngitis was associated with seronegative (OR 1.68, 95% CI 1.02–2.74) but not seropositive RA; chronic rhinitis/pharyngitis was associated with seropositive (OR 2.46, 95% CI 1.01–5.99) but not seronegative RA. Respiratory tract diseases tended towards higher associations in smokers, especially > 10 pack-years (OR 1.52, 95% CI 1.02–2.27, P = 0.10 for interaction).ConclusionAcute and chronic sinusitis, pharyngitis, and acute respiratory burden increased RA risk. The mucosal paradigm of RA pathogenesis may involve the upper respiratory tract.
- Published
- 2021
50. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
- Author
-
Peifeng Chen, Anita Arthur, Kaitlyn M. Morabito, Kristin Leach, Xiaolin Wang, Grace L. Chen, Attila Nagy, Lauren A. Chang, Jon Cooper, Amy L. Chamberlain, Janel Holland-Linn, Olga Vasilenko, Alicia T. Widge, Shufeng Bai, Judith A Stein, LaSonji A. Holman, Cristina Carter, Iris Pittman, Deepika Gollapudi, Lisa A. Kueltzo, Colleen Fridley, Michelle C. Crank, Amritha Menon, William Whalen, Mridul Ghosh, Cynthia S. Hendel, Martha Nason, Amy Liu, Althaf Hussain, Laura Novik, Pernell Williams, Maria Burgos Florez, Robert T. Bailer, Thuy Nguyen, Brenda Larkin, Tracy J. Ruckwardt, Pamela Costner, Lam Le, Zhong Zhao, Elizabeth Carey, Vera Ivleva, Jennifer Walters, John R. Mascola, Jennifer Cunningham, Olga Trofymenko, Ya-chen Chang, Somia P. Hickman, Martin R. Gaudinski, Richard M. Schwartz, Slobodanka D. Manceva, Kevin Carlton, Barney S. Graham, Rahul Ragunathan, Jason G. D. Gall, Ana M. Ortega-Villa, Colin Tran, Sarah H. Plummer, Abidemi Ola, Ro Shauna S Rothwell, Ingelise J. Gordon, Mingzhong Chen, Jamie G. Saunders, Aba Mensima Eshun, Bob C. Lin, Azad Kumar, Nina M. Berkowitz, Xun Liu, Cora Trelles Cartagena, Emily Phung, Galina Yamshchikov, Joe Horwitz, Sarah O’Connell, Florence Kaltovich, Floreliz Mendoza, LaShawn Requilman, Man Chen, Preeti Apte, Christopher Lee, and Renunda Hicks
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Allergy ,Adolescent ,medicine.medical_treatment ,Phases of clinical research ,Antibodies, Viral ,Article ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Internal medicine ,Respiratory Syncytial Virus Vaccines ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,business.industry ,Immunogenicity ,Infant ,Middle Aged ,medicine.disease ,Antibodies, Neutralizing ,Respiratory Syncytial Viruses ,Clinical trial ,Vaccination ,030228 respiratory system ,Tolerability ,Vaccines, Subunit ,business ,Adjuvant - Abstract
Multiple active vaccination approaches have proven ineffective in reducing the substantial morbidity and mortality caused by respiratory syncytial virus (RSV) in infants and older adults (aged ≥65 years). A vaccine conferring a substantial and sustainable boost in neutralising activity is required to protect against severe RSV disease. To that end, we evaluated the safety and immunogenicity of DS-Cav1, a prefusion F subunit vaccine.In this randomised, open-label, phase 1 clinical trial, the stabilised prefusion F vaccine DS-Cav1 was evaluated for dose, safety, tolerability, and immunogenicity in healthy adults aged 18-50 years at a single US site. Participants were assigned to receive escalating doses of either 50 μg, 150 μg, or 500 μg DS-Cav1 at weeks 0 and 12, and were randomly allocated in a 1:1 ratio within each dose group to receive the vaccine with or without aluminium hydroxide (AlOH) adjuvant. After 71 participants had been randomised, the protocol was amended to allow some participants to receive a single vaccination at week 0. The primary objectives evaluated the safety and tolerability at every dose within 28 days following each injection. Neutralising activity and RSV F-binding antibodies were evaluated from week 0 to week 44 as secondary and exploratory objectives. Safety was assessed in all participants who received at least one vaccine dose; secondary and exploratory immunogenicity analysis included all participants with available data at a given visit. The trial is registered with ClinicalTrials.gov, NCT03049488, and is complete and no longer recruiting.Between Feb 21, 2017, and Nov 29, 2018, 244 participants were screened for eligibility and 95 were enrolled to receive DS-Cav1 at the 50 μg (n=30, of which n=15 with AlOH), 150 μg (n=35, of which n=15 with AlOH), or 500 μg (n=30, of which n=15 with AlOH) doses. DS-Cav1 was safe and well tolerated and no serious vaccine-associated adverse events deemed related to the vaccine were identified. DS-Cav1 vaccination elicited robust neutralising activity and binding antibodies by 4 weeks after a single vaccination (p0·0001 for F-binding and neutralising antibodies). In analyses of exploratory endpoints at week 44, pre-F-binding IgG and neutralising activity were significantly increased compared with baseline in all groups. At week 44, RSV A neutralising activity was 3·1 fold above baseline in the 50 μg group, 3·8 fold in the 150 μg group, and 4·5 fold in the 500 μg group (p0·0001). RSV B neutralising activity was 2·8 fold above baseline in the 50 μg group, 3·4 fold in the 150 μg group, and 3·7 fold in the 500 μg group (p0·0001). Pre-F-binding IgG remained significantly 3·2 fold above baseline in the 50 μg group, 3·4 fold in the 150 μg group, and 4·0 fold in the 500 μg group (p0·0001). Pre-F-binding serum IgA remained 4·1 fold above baseline in the 50 μg group, 4·3 fold in the 150 μg group, and 4·8 fold in the 500 μg group (p0·0001). Although a higher vaccine dose or second immunisation elicited a transient advantage compared with lower doses or a single immunisation, neither significantly impacted long-term neutralisation. There was no long-term effect of dose, number of vaccinations, or adjuvant on neutralising activity.In this phase 1 study, DS-Cav1 vaccination was safe and well tolerated. DS-Cav1 vaccination elicited a robust boost in RSV F-specific antibodies and neutralising activity that was sustained above baseline for at least 44 weeks. A single low-dose of pre-F immunisation of antigen-experienced individuals might confer protection that extends throughout an entire RSV season.The National Institutes of Allergy and Infectious Diseases.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.